Aphaia Pharma’s Post

Allison Aubrey, NPR news correspondent and contributor, reports that a #drug taken by millions of people to control #diabetes may do more than lower blood sugar. Research suggests #metformin has anti-inflammatory effects that could help protect against common age-related diseases including #heartdisease, #cancer, and #cognitivedecline. Scientists who study the biology of aging have designed a clinical study, known as #TheTAMETrial, to test whether metformin can help prevent these diseases and promote a longer #healthspan in healthy, older adults. Currently the FDA doesn't recognize aging as a disease to treat, but the researchers hope this would usher in a paradigm shift — from treating each age-related medical condition separately, to treating these conditions together, by targeting aging itself. For now, metformin is only approved to treat type 2 diabetes in the U.S., but doctors can prescribe it off-label for conditions other than its approved use. Exciting news...would you try it? Please check with your doctor first before you do.

#ChronicKidneyDisease Diagnosis: A New Hope with #MachineLearning and #Metabolomics? https://lnkd.in/gjrebNXZ Chronic kidney disease (CKD) is a growing global health concern. Early #diagnosis is crucial for improving patient outcomes, but current methods have limitations. We're excited to share a new case study exploring the potential of #metabolomics and machine learning for earlier and more accurate CKD diagnosis. This promising study offers a glimpse into the future of personalized medicine for kidney health. MetwareBio offers metabolomics services for CKD research. #Healthcare #EarlyDetection #humanhealth

About 1.5 million adults in the U.S. are living with rheumatoid arthritis (RA). Treatments often do a good job fighting inflammation to slow or even stop joint damage and ease pain. But this doesn’t work for everyone. Why is that? A new study has an intriguing answer. Read more from the NIH Director’s Blog: https://lnkd.in/ePWPxJtD #ArthritisAwarenessMonth

New AMRA Medical insights shared at ICFSR CONGRESS correlate adverse muscle composition in chronic kidney disease (CKD) with poor functional performance & increased comorbidity. A recent study reveals how muscle composition markers derived from AMRA’s innovative MRI-based body composition platform can identify vulnerable individuals within CKD and their associated comorbidity risk. The findings of the study, which were shared at the 2024 International Conference on Frailty and Sarcopenia Research (ICFSR) this past Thursday, emphasize the important role muscle composition plays in identifying risk populations for comorbid conditions associated with metabolic and chronic disease. Read more about the study here: https://lnkd.in/dAQTz8Rb #ICFSR24 #AMRAMedical #MuscleComposition #ChronicKidneyDisease #Sarcopenia #Frailty #precisionmedicine #neuromusculardisease #MRI #clinicalresearch

What's the Secret to Living to 100? Centenarians' Blood Tests Might Hold Clues https://lnkd.in/gEtRHJtQ. The answers to why some people live to age 100 and others do not may lie in understanding the metabolic profiles of centenarians. New research shows that centenarians—or people who live to 100 or beyond—may have lower (but not too low) levels of glucose, uric acid, and creatinine in their blood. Those differences in blood biomarkers were also seen as early as 65 years old, suggesting healthier overall lifestyles for a longer period of time. Reference on study is below: "Blood biomarker profiles and exceptional longevity: comparison of centenarians and non-centenarians in a 35-year follow-up of the Swedish AMORIS cohort" For the study, researchers used data from 44,636 people who were part of the AMORIS (Apolipoprotein-related MOrtality RISk) cohort, who received routine and outpatient clinical laboratory testing at the Central Automation Laboratory in Stockholm, Sweden between 1985 and 1996. #innovation #medicine

In a recent study in #Med, authors validated the #LiverRisk score using large population samples from US NHANES and UK Biobank. The LiverRisk score outperforms existing methods in predicting liver fibrosis and can identify individuals with a higher risk of death from liver or diabetes complications. Furthermore, it offers a cost-effective approach compared to prior methods. https://lnkd.in/e_8TCU4X #LiverHealth #Fibrosis #LiverRiskScore #NoninvasiveTest #EarlyDetection #MortalityPrediction #CostEffectiveness

Our recent paper demonstrates the cumulative impact of #metabolic #syndrome #MetS components on micro- and macrovascular disease in metabolic dysfunction-associated steatotic liver disease #MASLD We utilised the large real world data #RWD ecosystem, TriNetX We demonstrate a differential effect of #metabolic #syndrome components on micro- and macrovascular disease risk in patients with #MASLD, with a cumulative impact of multiple MetS on overall risk. #MASLD with all #metabolic #syndrome components carried greatest risk of both micro- and macrovascular disease. https://lnkd.in/ekn5WDCJ Thank you to TriNetX for the continuing collaboration and for my excellent research fellow, Dr Alex Henney for leading on this piece of work Gema Hernández Ibarburu Philip Austin Gadi Lachman Gavin Soady David Perez del Rey

Ozempic and #Wegovy may #reduce #inflammation by #targeting the #brain #Ozempic is a diabetes treatment, but it is often also used to help with weight lossfcm82/Shutterstock Weight-loss and diabetes injections such as Wegovy and https://lnkd.in/gdcsShvb #adviceguru #obesity #science #weightloss

🧬🔍Alzheimer's disease affects millions worldwide, presenting a pressing health crisis. Traditionally, therapies have targeted amyloid plaques, but recent failures have shifted focus to tau protein, a key player in cognitive decline. This article delves into the current landscape of tau-targeting therapies, marking a crucial turning point in AD treatment. While past approaches faced hurdles, immunotherapies in clinical trials offer new hope. Targeting tau, which closely correlates with cognitive impairments, holds promise for more effective interventions.💫 Read the full article: https://lnkd.in/dwYHH37T #AlzheimersResearch #TauTherapies #MedicalBreakthroughs #Anogen